ArticleCureus2026
Hemophagocytic Lymphohistiocytosis-Macrophage Activation Syndrome (HLH-MAS) Mimicking Neuropsychiatric Lupus in Systemic Lupus Erythematosus (SLE).
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lymphohistiocytosis-macrophage activation syndrome (HLH-MAS) is a life-threatening hyperinflammatory syndrome that can complicate systemic lupus erythematosus (SLE) and present with neurologic manifestations that mimic neuropsychiatric SLE (NPSLE). A 28-year-old woman with a four-year history of SLE initially presented to the emergency department of a community hospital with acute altered mental status and mutism. Laboratory evaluation revealed pancytopenia, markedly elevated ferritin (8,670 ng/mL), hypertriglyceridemia, and hypofibrinogenemia with an erythrocyte sedimentation rate (ESR) that declined from 21 to 6 mm/hr despite active inflammation, a recognized clue distinguishing HLH-MAS from NPSLE. Extensive infectious workup was negative. Although bone marrow biopsy and specialized biomarkers were unavailable at the presenting community hospital, an HScore of 271 (>99% probability of reactive hemophagocytic syndrome) strongly supported the diagnosis of HLH-MAS. High-dose IV methylprednisolone resulted in a progressive decline in ferritin and partial improvement in clinical status, following which the patient was transferred to a tertiary care center for further management. Early recognition of HLH-MAS in SLE patients presenting with acute neurologic symptoms is critical, as misdiagnosis can delay appropriate treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.